National Comprehensive Cancer Network

Home | About NCCN | Find a Member Institution | Login/Register | Contact Us

NCCN 19^th Annual Conference: Advancing the Standard of Cancer Care™

NCCN Annual Congress: Hematologic Malignancies™

2013 Sponsor & Exhibitor Prospectus

2013 Advertising Rate Card

NCCN Academy for Excellence & Leadership in Oncology™

NCCN Academy for Excellence and Leadership in Oncology™

License NCCN Academy Video Modules!

Customize your own NCCN Academy Curriculum

About NCCN Academy

NCCN Oncology Policy Program

Comparative Effectiveness in Cancer Care

Recommendations for REMS Stakeholders

NCCN Patient Advocacy Summit

Off-Label Drug Use and Compendia

Molecular Testing – Effectiveness, Efficiency, and Reimbursement

NCCN Patient Advocacy Summit: Ensuring Optimal Care for Patients

Equity in Cancer Care: Pathways, Protocols, and Guidelines

Data Needs in Oncology – Clinical, Regulatory, Coverage, and Policy Issues

Patient Advocacy: Patient Perspectives Across the Cancer Care Continuum

Evolving Policy Issues in Oncology – Revisiting Biosimilars and Molecular Testing

Measuring Quality in Oncology – Challenges and Opportunities

NCCN Online CME/CE

Interactive CME

Supporter Opportunities

Educational Events & Programs

NCCN 8^th Annual Congress:
Hematologic Malignancies™
September 20 – 21, 2013

New York Marriott Marquis
New York, New York

Overview

Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This Congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.

Moderator:
Andrew D. Zelenetz, MD, PhD
Memorial Sloan-Kettering Cancer Center

Agenda

Friday, September 20, 2013
4:30 – 6:30 PM	Registration, Exhibits, and Reception
6:00 – 8:45 PM	Scientific Sessions

Saturday, September 21, 2013
7:00 – 8:00 AM	Registration, Exhibits, and Breakfast
8:00 AM – 12:30 PM	Scientific Sessions
12:30 – 1:45 PM	Lunch and Exhibits
1:45 – 5:00 PM	Scientific Sessions
Faculty and sessions will be added as they are confirmed.

Highlights*

Molecular Monitoring in CML and ALL
TKI Therapy in CML: Practical Considerations
Management of Philadelphia (Ph)-Positive ALL
PET-Guided Response Assessment and Risk-Adapted Therapy in Hodgkin’s Lymphoma
Lymphocyte Predominant Hodgkin's Lymphoma (LPHL)
Management of Relapsed/Refractory Multiple Myeloma
Management of Bone Health in Multiple Myeloma
Current Treatment Approaches in APL
Clinical Genomics in Myeloid Malignancies
Current Practices in the Management of Cancer Therapy-Induced Emesis
Palliative Care for Hematologic Malignancies
Targeting Novel Signaling Pathways in B-cell Malignancies
Current Practices in NHL Therapy: Focus on Marginal Zone Lymphomas
Diagnosis and Management of Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Supportive Care Considerations in the Treatment of NHL
Management of Pain in Patients with Hematologic Malignancies
Alternative Stem Cell Sources and Transplantation

*Subject to change as the agenda is finalized.

Exhibitor Information

Organizations who are interested in exhibiting at NCCN programs are encouraged to contact Jennifer Tredwell, Director, Marketing.

Please check back often for the most up-to-date information. Please contact 866.788.NCCN (6226) or send an e-mail if you have additional questions.

The NCCN 7^th Annual Congress: Hematologic Malignancies™ was held September 14 – 15, 2012 in New York, NY.

View a brief summary of this meeting.
View recorded presentations at education.nccn.org/hem2012.